The agreement to conduct feasibility studies is generally a positive development, suggesting advancement in Instil Bio's pipeline. However, the closure of UK operations introduces uncertainty about the company's strategic direction and cost structure. This could have a neutral short-term impact as the market digests both the potential benefits of the research agreement and the implications of the operational shutdown.